Clinical TrialMay 14, 2026, 09:07 AM
CAMP4 CMP-002 Preclinical Data Improves Seizures in SYNGAP1 Disorder
AI Summary
CAMP4 Therapeutics announced new preclinical data for CMP-002, its lead investigational therapeutic candidate for SYNGAP1-related disorder (SRD). The data, presented at the TIDES conference, showed statistically significant improvements in seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model. These findings build upon prior preclinical evidence of neurodevelopmental benefits, suggesting CMP-002 has the potential for broad therapeutic impact by restoring SYNGAP1 protein levels. The company plans to initiate a Phase 1/2 clinical trial for CMP-002 in SRD patients in the second half of 2026.
Key Highlights
- CMP-002 demonstrated statistically significant improvement in seizure threshold in a SYNGAP1 haploinsufficient mouse model.
- CMP-002 led to a statistically significant decrease in seizure severity in the mouse model.
- These preclinical results suggest CMP-002 may improve both neurodevelopmental and seizure phenotypes in SYNGAP1-related disorder.
- CAMP4 expects to advance CMP-002 into a Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder in 2H 2026.
Price Impact
More from CAMP